Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
On outskirts of Doha, laborers watch World Cup they built
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
On outskirts of Doha, laborers watch World Cup they built
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
On outskirts of Doha, laborers watch World Cup they built
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
S&P 500   4,026.12
DOW   34,347.03
QQQ   286.92
Considerations When Rolling Over a 401(k) into a Roth IRA
See how to make money instead of spending it on Black Friday with this offer (Ad)
Sober or bright? Europe faces holidays during energy crunch
Biden eases Venezuela sanctions as opposition talks resume
See how to make money instead of spending it on Black Friday with this offer (Ad)
On outskirts of Doha, laborers watch World Cup they built
Whole Foods decision to pull lobster divides enviros, pols
See how to make money instead of spending it on Black Friday with this offer (Ad)
Railway workers in Austria to strike Monday in pay standoff
Airbnb has a plan to fix cleaning fees
NASDAQ:CHRS

Coherus BioSciences - CHRS Stock Forecast, Price & News

$6.58
+0.03 (+0.46%)
(As of 11/25/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.47
$6.60
50-Day Range
$6.55
$10.07
52-Week Range
$5.60
$18.94
Volume
239,423 shs
Average Volume
1.11 million shs
Market Capitalization
$511.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

Coherus BioSciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
150.8% Upside
$16.50 Price Target
Short Interest
Bearish
12.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.08
Upright™ Environmental Score
News Sentiment
0.85mentions of Coherus BioSciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.87) to ($1.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

626th out of 1,044 stocks

Biological Products, Except Diagnostic Industry

104th out of 174 stocks

CHRS stock logo

About Coherus BioSciences (NASDAQ:CHRS) Stock

Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.

Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Stock News Headlines

Coherus BioSciences Earnings Preview
Will Coherus BioSciences (CHRS) Stock Bounce Back?
Coherus BioSciences (NASDAQ: CHRS)
Mizuho Securities Keeps Their Buy Rating on Coherus Biosciences (CHRS)
Coherus: 2022 Is In Many Ways A Make Or Break Year
See More Headlines
Receive CHRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coherus BioSciences and its competitors with MarketBeat's FREE daily newsletter.

CHRS Company Calendar

Last Earnings
11/07/2021
Today
11/27/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/16/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CHRS
Fax
N/A
Employees
332
Year Founded
2010

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
+150.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-287,100,000.00
Net Margins
-116.54%
Pretax Margin
-116.54%

Debt

Sales & Book Value

Annual Sales
$326.55 million
Book Value
($1.25) per share

Miscellaneous

Free Float
68,515,000
Market Cap
$511.79 million
Optionable
Optionable
Beta
1.03

Social Links


Key Executives

  • Mr. Dennis M. LanfearMr. Dennis M. Lanfear (Age 67)
    Chairman, Pres & CEO
    Comp: $1.86M
  • Mr. McDavid StilwellMr. McDavid Stilwell (Age 50)
    Chief Financial Officer
    Comp: $756k
  • Mr. Vladimir Vexler Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $778.28k
  • Mr. Bryan J. Mcmichael (Age 44)
    Sr. VP of Accounting, Principal Accounting Officer & Corp. Controller
  • Mr. Richard L. Hameister
    Chief Technical Officer
  • Mr. Christopher W. Slavinsky (Age 49)
    Chief Bus. & Legal Officer
  • Cheston Turbyfill
    VP of Communications
  • Ms. Karen Kotz
    Exec. VP of Sales & Strategic Accounts
  • Ms. Rebecca Sunshine (Age 59)
    Chief HR Officer
  • Mr. Michael Chen
    Sr. VP of Commercial Analytics & Trade













CHRS Stock - Frequently Asked Questions

Should I buy or sell Coherus BioSciences stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CHRS shares.
View CHRS analyst ratings
or view top-rated stocks.

What is Coherus BioSciences' stock price forecast for 2023?

4 brokers have issued 1 year price targets for Coherus BioSciences' shares. Their CHRS share price forecasts range from $7.00 to $30.00. On average, they expect the company's share price to reach $16.50 in the next year. This suggests a possible upside of 150.8% from the stock's current price.
View analysts price targets for CHRS
or view top-rated stocks among Wall Street analysts.

How have CHRS shares performed in 2022?

Coherus BioSciences' stock was trading at $15.96 at the start of the year. Since then, CHRS stock has decreased by 58.8% and is now trading at $6.58.
View the best growth stocks for 2022 here
.

When is Coherus BioSciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our CHRS earnings forecast
.

How were Coherus BioSciences' earnings last quarter?

Coherus BioSciences, Inc. (NASDAQ:CHRS) announced its quarterly earnings results on Sunday, November, 7th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.12. The biotechnology company earned $82.50 million during the quarter, compared to the consensus estimate of $86.96 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 422.10% and a negative net margin of 116.54%. During the same period last year, the business posted $0.33 earnings per share.

What is Dennis M. Lanfear's approval rating as Coherus BioSciences' CEO?

21 employees have rated Coherus BioSciences Chief Executive Officer Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among the company's employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Coherus BioSciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

What is Coherus BioSciences' stock symbol?

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Who are Coherus BioSciences' major shareholders?

Coherus BioSciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (16.69%), Alliancebernstein L.P. (7.85%), Vanguard Group Inc. (6.72%), State Street Corp (6.56%), Disciplined Growth Investors Inc. MN (1.46%) and Peregrine Capital Management LLC (1.45%). Insiders that own company stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends
.

How do I buy shares of Coherus BioSciences?

Shares of CHRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Coherus BioSciences' stock price today?

One share of CHRS stock can currently be purchased for approximately $6.58.

How much money does Coherus BioSciences make?

Coherus BioSciences (NASDAQ:CHRS) has a market capitalization of $511.79 million and generates $326.55 million in revenue each year. The biotechnology company earns $-287,100,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis.

How many employees does Coherus BioSciences have?

The company employs 332 workers across the globe.

Does Coherus BioSciences have any subsidiaries?
The following companies are subsidiares of Coherus BioSciences: Coherus Intermediate Corp, InteKrin, InteKrin Russia, and InteKrin Therapeutics Inc..
Read More
How can I contact Coherus BioSciences?

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The official website for the company is www.coherus.com. The biotechnology company can be reached via phone at (650) 649-3530 or via email at darrington@coherus.com.

This page (NASDAQ:CHRS) was last updated on 11/27/2022 by MarketBeat.com Staff